Consecutive IL-2 and IFN-α2a maintenance in a patient with acute non-lymphoblastic leukemia and renal cell cancer

A. Uysal, M. Özcan, C. Üstün, S. Fenkçi

Research output: Contribution to journalArticlepeer-review

Abstract

Over the last few years, the use of interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells have been found to be effective in the treatment of some solid tumours and acute myeloid leukemia. Our patient was initially diagnosed as having bilateral synchronous renal cell cancer (RCC) and underwent nephrectomy. Approximately two years after the operation he developed leukopenia without any sign of residual renal cell cancer. Bone marrow examination revealed acute myeloblastic leukemia (AML). IL-2 following IFN-α2a was used as a maintenance therapy after a standard remission induction and a consolidation therapy. Our patient has been still disease free for 58 months after the diagnosis of AML and 71 months after the diagnosis renal cell cancer. Review of the literature showed that this is the first case who has both RCC and AML and was treated successfully with IL-2 and IFN-α2a.

Original languageEnglish (US)
Pages (from-to)207-210
Number of pages4
JournalTurkish Journal of Haematology
Volume18
Issue number3
StatePublished - 2001

Keywords

  • ANLL
  • IFN-α2a
  • IL-2
  • Renal cell cancer

Fingerprint

Dive into the research topics of 'Consecutive IL-2 and IFN-α2a maintenance in a patient with acute non-lymphoblastic leukemia and renal cell cancer'. Together they form a unique fingerprint.

Cite this